[anecdote] Beyond weight loss: cognitive benefits, lowered inflammation, and reduced thyroid-peroxidase antibodies in a Hashimoto’s patient. — Koniver 00:17–00:18
[anecdote] GLP-1 class traces to Gila-monster saliva GLP-1 (pharma extended the half-life). Weight is a brain set-point computed from gut hormones; GLP-1 is a strong ‘don’t-eat’ signal. Bakri’s 1 mg Ozempic self-test (skipping titration) → severe vomiting — titrate slowly. — Bakri 02:24–02:33
[educational] GLP-1-receptor class; class benefits plateau (weight loss above subQ semaglutide 7.2 mg / oral 25–50 mg) with diminishing returns vs rising GI side effects. — Oral GLP-1 review ~00:15
[educational] GLP-1 class ranked the #1 longevity peptide group (all-cause-mortality and dementia-risk reductions; longevity mechanisms beyond weight loss). — Longevity Top-5
[literature] Class-level breast-cancer INCIDENCE signal too: GLP-1 RA exposure linked to ~25–37% lower odds of developing breast cancer in 94,827 cancer-free women (ASCO 2026 Abstract 10506, JCO Oncology Practice). Class-level/observational — the incidence cohort pooled GLP-1 RAs; a separate ASCO progression analysis found tirzepatide did not reach significance where semaglutide/liraglutide/dulaglutide did. — SOURCE-glp1-breast-cancer-incidence-mcdonald-2026
Physician protocols
[protocol]Micro-dose compounded; start low and go slow; keep loss ≤2 lb/week to preserve lean mass; adequate protein + resistance training; avoid rapid loss (‘Ozempic face’). Compound with sermorelin to offset muscle loss. — Koniver 00:15–00:18, 00:37